{"id":47513,"date":"2024-04-01T10:11:33","date_gmt":"2024-04-01T10:11:33","guid":{"rendered":"https:\/?p=47513"},"modified":"2024-04-01T10:11:55","modified_gmt":"2024-04-01T10:11:55","slug":"stoke-therapeutics-soars-73-on-drug-trial-success-investor-alert","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/stoke-therapeutics-soars-73-on-drug-trial-success-investor-alert\/","title":{"rendered":"Stoke Therapeutics Soars 73% on Drug Trial Success"},"content":{"rendered":"<p><span style=\"font-weight: 400;\"><strong><a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NSD\/STOK\">Stoke Therapeutics Inc (STOK: NSD<\/a><\/strong>) saw its stock price soar 73% today after releasing encouraging data from a Phase 1\/2 clinical trial for STK-001. This drug candidate targets Dravet syndrome, a rare and severe form of epilepsy in children.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><strong>Positive Results Pave the Way for Phase 3:<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">The positive data not only boosted investor confidence but also received FDA clearance for specific dosage levels. This green light allows Stoke to proceed with a Phase 3 trial, a crucial step towards potentially bringing STK-001 to market.<\/span><\/p>\n<p><!-- STA Widget BEGIN --><\/p>\n<div>\n<div class=\"sta-analyst-rating-widget-display\">\n<p><a style=\"text-decoration: none; color: #4b6db5 !important;\" href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NSD\/STOK\" target=\"_blank\" rel=\"noopener\">STOK Ratings<\/a> by Stock Target Advisor<\/p>\n<\/div>\n<p><script class=\"analyst-rating\" type=\"text\/javascript\" src=\"https:\/\/www.stocktargetadvisor.com\/assets\/js\/analyst_rating_widget.js\" data-symbol=\"STOK\" data-theme=\"wt_bg_dark\" data-uid=\"1244572210660a869a24285660a869a24286\" data-width=\"700\" >\n\t\t<\/script><\/p>\n<\/div>\n<h2><strong>Analysts Bullish on Stoke&#8217;s Future:<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">Wall Street analysts are overwhelmingly optimistic about Stoke&#8217;s future. The strong showing in the Phase 1\/2 trial prompted Needham analyst Joseph Stringer to upgrade his rating to &#8220;Buy&#8221; and significantly raise the price target for STOK. The overall analyst consensus echoes this sentiment, with eight analysts recommending a &#8220;Strong Buy&#8221; and an average price target suggesting a potential upside of 64%.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><strong>Bottom Line:\u00a0<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">While the recent developments are undeniably positive, investors should be aware that the drug development process is lengthy and carries inherent risks. Careful consideration of risk tolerance is essential before making any investment decisions.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Stoke Therapeutics Inc (STOK: NSD) saw its stock price soar 73% today after releasing encouraging data from a Phase 1\/2 clinical trial for STK-001. This&#8230;<\/p>\n","protected":false},"author":17,"featured_media":35648,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-47513","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Stoke Therapeutics Soars 73% on Drug Trial Success<\/title>\n<meta name=\"description\" content=\"Stoke Therapeutics surges 73% after positive data in a Dravet syndrome drug trial. Phase 3 greenlit, analysts bullish.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/stoke-therapeutics-soars-73-on-drug-trial-success-investor-alert\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Stoke Therapeutics Soars 73% on Drug Trial Success\" \/>\n<meta property=\"og:description\" content=\"Stoke Therapeutics surges 73% after positive data in a Dravet syndrome drug trial. Phase 3 greenlit, analysts bullish.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/stoke-therapeutics-soars-73-on-drug-trial-success-investor-alert\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-01T10:11:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-01T10:11:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2023\/06\/Frame-7-8.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Muzzammil Ahmad\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@https:\/\/x.com\/Muzzammil625\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Muzzammil Ahmad\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/stoke-therapeutics-soars-73-on-drug-trial-success-investor-alert\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/stoke-therapeutics-soars-73-on-drug-trial-success-investor-alert\/\"},\"author\":{\"name\":\"Muzzammil Ahmad\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\"},\"headline\":\"Stoke Therapeutics Soars 73% on Drug Trial Success\",\"datePublished\":\"2024-04-01T10:11:33+00:00\",\"dateModified\":\"2024-04-01T10:11:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/stoke-therapeutics-soars-73-on-drug-trial-success-investor-alert\/\"},\"wordCount\":196,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News &amp; Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/stoke-therapeutics-soars-73-on-drug-trial-success-investor-alert\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/stoke-therapeutics-soars-73-on-drug-trial-success-investor-alert\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/stoke-therapeutics-soars-73-on-drug-trial-success-investor-alert\/\",\"name\":\"Stoke Therapeutics Soars 73% on Drug Trial Success\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2024-04-01T10:11:33+00:00\",\"dateModified\":\"2024-04-01T10:11:55+00:00\",\"description\":\"Stoke Therapeutics surges 73% after positive data in a Dravet syndrome drug trial. Phase 3 greenlit, analysts bullish.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/stoke-therapeutics-soars-73-on-drug-trial-success-investor-alert\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/stoke-therapeutics-soars-73-on-drug-trial-success-investor-alert\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/stoke-therapeutics-soars-73-on-drug-trial-success-investor-alert\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Stoke Therapeutics Soars 73% on Drug Trial Success\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\",\"name\":\"Muzzammil Ahmad\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"caption\":\"Muzzammil Ahmad\"},\"description\":\"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/\",\"https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625\"],\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Stoke Therapeutics Soars 73% on Drug Trial Success","description":"Stoke Therapeutics surges 73% after positive data in a Dravet syndrome drug trial. Phase 3 greenlit, analysts bullish.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/stoke-therapeutics-soars-73-on-drug-trial-success-investor-alert\/","og_locale":"en_US","og_type":"article","og_title":"Stoke Therapeutics Soars 73% on Drug Trial Success","og_description":"Stoke Therapeutics surges 73% after positive data in a Dravet syndrome drug trial. Phase 3 greenlit, analysts bullish.","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/stoke-therapeutics-soars-73-on-drug-trial-success-investor-alert\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2024-04-01T10:11:33+00:00","article_modified_time":"2024-04-01T10:11:55+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2023\/06\/Frame-7-8.png","type":"image\/png"}],"author":"Muzzammil Ahmad","twitter_card":"summary_large_image","twitter_creator":"@https:\/\/x.com\/Muzzammil625","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"Muzzammil Ahmad","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/stoke-therapeutics-soars-73-on-drug-trial-success-investor-alert\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/stoke-therapeutics-soars-73-on-drug-trial-success-investor-alert\/"},"author":{"name":"Muzzammil Ahmad","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8"},"headline":"Stoke Therapeutics Soars 73% on Drug Trial Success","datePublished":"2024-04-01T10:11:33+00:00","dateModified":"2024-04-01T10:11:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/stoke-therapeutics-soars-73-on-drug-trial-success-investor-alert\/"},"wordCount":196,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News &amp; Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/stoke-therapeutics-soars-73-on-drug-trial-success-investor-alert\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/stoke-therapeutics-soars-73-on-drug-trial-success-investor-alert\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/stoke-therapeutics-soars-73-on-drug-trial-success-investor-alert\/","name":"Stoke Therapeutics Soars 73% on Drug Trial Success","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2024-04-01T10:11:33+00:00","dateModified":"2024-04-01T10:11:55+00:00","description":"Stoke Therapeutics surges 73% after positive data in a Dravet syndrome drug trial. Phase 3 greenlit, analysts bullish.","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/stoke-therapeutics-soars-73-on-drug-trial-success-investor-alert\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/stoke-therapeutics-soars-73-on-drug-trial-success-investor-alert\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/stoke-therapeutics-soars-73-on-drug-trial-success-investor-alert\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Stoke Therapeutics Soars 73% on Drug Trial Success"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8","name":"Muzzammil Ahmad","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","caption":"Muzzammil Ahmad"},"description":"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.","sameAs":["https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/","https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625"],"url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/47513","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=47513"}],"version-history":[{"count":2,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/47513\/revisions"}],"predecessor-version":[{"id":47516,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/47513\/revisions\/47516"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/35648"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=47513"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=47513"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=47513"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}